Organizational restructuring centered on SBUs, production companies and customer centers

「This absorption-type company split is based on the concept of creating a “new Daicel.” By integrating the subject business of Polyplastics into the Company, we aim to maximize corporate value through (1) sharing Polyplastics’ expertise in technical services and solution provision, (2) closer coordination with the Company’s Safety and Materials businesses, among others, (3) utilizing human resources to support growth across the Group, and (4) improving the efficiency of corporate functions.」

「2027年3月期からのセグメント変更」

「During the current interim consolidated accounting period, the Company transferred the resin compounding business of consolidated subsidiary ダイセルミライズ㈱ to equity-method affiliate ノバセル㈱.」

「In addition, from the first quarter of the current consolidated fiscal year, the Company reclassified 1,3-butylene glycol, a cosmetic ingredient previously included in “Medical and Healthcare,” to “Materials,” and reclassified the research and development function for new medical devices, previously included in “Safety,” to “Medical and Healthcare.”」

「In April 2023, the Company established the Life Sciences SBU. The Life Sciences Business Planning Office had previously formulated and advanced business and R&D strategies for the Group's healthcare-related businesses and prepared for the transition to an SBU. As the direction and business strategy of the business became clear, it changed to the Life Sciences SBU.」

「The Company also established the Life Sciences Business Planning Office, which consolidates products and services, research and development, and marketing functions related to the medical field, with the aim of converting the medical field into an SBU by strengthening needs identification and expanding business synergies.」

「To maximize synergies from making Polyplastics a wholly owned subsidiary, the Company newly established the Performance Materials Business Headquarters. The president of Polyplastics will concurrently serve as the Company’s senior executive officer and head of the headquarters, working to strengthen the Group’s overall resins business.」

「Effective 1 July 2020, the Company transferred the automotive products business of its consolidated subsidiary ダイセルポリマー㈱ to the Company and changed its segment classification from Engineering Plastics to Safety. In addition, the general-purpose resins business of consolidated subsidiaries ダイセルファインケム㈱ and ダイセルポリマー㈱ and the packaging applications business of ダイセルバリューコーティング㈱ were consolidated into consolidated subsidiary ダイセルミライズ㈱, with ダイセルファインケム㈱ as the surviving company.」

「Following the transition to an organization centered on “strategic business units (SBUs)” from the first quarter of the current consolidated fiscal year, the Company changed its reportable segments from the four previous categories of “Cellulose,” “Organic Synthesis,” “Synthetic Resins” and “Pyrotechnic Products” to five categories: “Medical and Healthcare,” “Smart,” “Safety,” “Materials” and “Engineering Plastics.”」

「We have established a “value-creation strategic business unit (SBU)” that provides value shared across markets, and a “materials-provision SBU” that provides added value through chains of technologies and materials, assigning them business planning, marketing and research and development functions. Production functions are being consolidated into two “production companies” based on common core technologies, while order processing, production planning and logistics functions are being integrated into a “customer center.” Through these measures, we are pursuing greater competitiveness by further improving productivity, including quality and costs, and increasing efficiency across the entire value chain.」